Prevalence and distribution of human papillomavirus (HPV) serotypes of the anogenital region in adolescent boys and young men: a systematic review
Keywords:
HPV; adolescent boys; HPV vaccine; seroprevalenceAbstract
The objective of this study is to investigate the impact of HPV vaccinations on the prevalence of HPV serotypes on adolescent boys and young men through a systematic review. The search aimed for clinical studies in English up to 2022 concerning HPV serotyping of samples from randomly selected, non-high risk male participants, aged 11-25 with no underlying pathologies. The search resulted in 18 eligible articles among which 15 concerned unvaccinated and 3 concerned vaccinated young males. In 4 articles the participants were homosexual/bisexual, in 4 they were heterosexual while in the rest of the publications the sexual orientation of participants was mixed or unspecified. In about half of the articles, sample collection predated the initiation of national HPV vaccination programs for girls in the respective countries. In the selected articles, HPV seroprevalence varied significantly depending on vaccination rates and variability in methodology. Overall HPV prevalence was found to be high in most studies. Significant reduction of HPV vaccine-type prevalence was detected only in directly vaccinated adolescent boys and young men.
References
WHO (2017) ‘Human papillomavirus vaccines: WHO position paper, May
-Recommendations’, Vaccine. Elsevier, 35(43), pp. 5753-5755.
Bosch, F. X. et al. (2008) ‘Epidemiology and Natural History of Hu-
man Papillomavirus Infections and Type-Specific Implications in Cer-
vical Neoplasia’, Vaccine, 26, pp. K1-K16. doi: https://doi.org/10.1016/
j.vaccine.2008.05.064.
de Martel, C. et al. (2017) ‘Worldwide burden of cancer attributable
to HPV by site, country and HPV type’, International Journal of Cancer.
John Wiley & Sons, Ltd, 141(4), pp. 664-670. doi: <https://doi.org/
1002/ijc.30716>.
Bruni, L. et al. (2021) ‘HPV vaccination introduction worldwide and
WHO and UNICEF estimates of national HPV immunization coverage
-2019’, Preventive Medicine, 144, p. 106399. doi: https://doi.org/
1016/j.ypmed.2020.106399.
Drolet, M. et al. (2015) ‘Population-level impact and herd effects
following human papillomavirus vaccination programmes: A systemat-
ic review and meta-analysis’, The Lancet Infectious Diseases, 15(5), pp.
-580. doi: 10.1016/S1473-3099(14)71073-4.
Arbyn, M., Smith, S. B., et al. (2018) ‘Detecting cervical precancer and
reaching underscreened women by using HPV testing on self samples: updated
meta-analyses’, Bmj. British Medical Journal Publishing Group, 363.
de Oliveira, C. M., Fregnani, J. H. T. G. and Villa, L. L. (2019) ‘HPV Vaccine: Updates
and Highlights’, Acta Cytologica, 63(2), pp. 159-168. doi: 10.1159/000497617.
WHO (2006) Comprehensive cervical cancer control: a guide to essential
practice. World Health Organization.
Bogaards, J. A. et al. (2015) ‘Direct benefit of vaccinating boys along with girls
against oncogenic human papillomavirus: bayesian evidence synthesis’, BMJ :
British Medical Journal, 350, p. h2016. doi: 10.1136/bmj.h2016.
Elfström, K. M. et al. (2016) ‘Human papillomavirus vaccination of boys and
extended catch-up vaccination: effects on the resilience of programs’, The
Journal of infectious diseases. Oxford University Press, 213(2), pp. 199-205.
Näsman, A., Du, J. and Dalianis, T. (2020) ‘A global epidemic increase of an
HPV‐induced tonsil and tongue base cancer-potential benefit from a pan‐
gender use of HPV vaccine’, Journal of internal medicine. Wiley Online Library,
(2), pp. 134-152.
Prue, G. et al. (2018) ‘It is time for universal HPV vaccination’, The Lancet.
Elsevier, 392(10151), pp. 913-914.
Cheng, L., Wang, Y. and Du, J. (2020) ‘Human papillomavirus vaccines: an
updated review’, Vaccines. Multidisciplinary Digital Publishing Institute, 8(3), p.
Page, M. J. et al. (2021) ‘The PRISMA 2020 statement: an updated guideline
for reporting systematic reviews’, Systematic reviews. BioMed Central, 10(1),
pp. 1-11.
Gargano, J. W. et al. (2017) ‘Prevalence of genital human papillomavirus in
males, United States, 2013-2014’, The Journal of infectious diseases. Oxford
University Press US, 215(7), pp. 1070-1079.
Chow, E. P. F. et al. (2021) ‘Prevalence of human papillomavirus in young
men who have sex with men after the implementation of gender-neutral HPV
vaccination: a repeated cross-sectional study’, The Lancet Infectious Diseases.
Elsevier, 21(10), pp. 1448-1457.
Lehtinen, T. et al. (2017) ‘Human papillomavirus (HPV) prevalence in male
adolescents 4 years after HPV-16/18 vaccination’, The Journal of Infectious
Diseases. Oxford University Press US, 216(8), pp. 966-968.
Bianchi, S. et al. (2013) ‘Detection and genotyping of human papillomavirus
in urine samples from unvaccinated male and female adolescents in Italy’, PLoS
One. Public Library of Science San Francisco, USA, 8(11), p. e79719.
Sonnenberg, P. et al. (2013) ‘Prevalence, risk factors, and uptake of in-
terventions for sexually transmitted infections in Britain: findings from the Na-
tional Surveys of Sexual Attitudes and Lifestyles (Natsal)’, The Lancet. Elsevier,
(9907), pp. 1795-1806.
Hussain, S. et al. (2012) ‘Human papillomavirus infection among young ado-
lescents in India: impact of vaccination’, Journal of medical virology. Wiley On-
line Library, 84(2), pp. 298-305.
O’leary, M. C. et al. (2011) ‘HPV type-specific prevalence using a urine assay
in unvaccinated male and female 11-to 18-year olds in Scotland’, British Journal
of Cancer. Nature Publishing Group, 104(7), pp. 1221-1226.
Weaver, B. A. et al. (2004) ‘Evaluation of Genital Sites and Sampling Tech-
niques for Detection of Human Papillomavirus DNA in Men’, The Journal of In-
fectious Diseases, 189(4), pp. 677-685. doi: 10.1086/381395.
Baussano, I. et al. (2016) ‘Human papillomavirus vaccination at a time of
changing sexual behavior’, Emerging infectious diseases. Centers for Disease
Control and Prevention, 22(1), p. 18.
Kreimer, A. R. et al. (2004) ‘Gender differences in sexual biomarkers and
behaviors associated with human papillomavirus-16,-18, and-33 seroprevalence’,
Sexually transmitted diseases. JSTOR, pp. 247-256.
Chambers, C. et al. (2022) ‘Anal Human Papillomavirus Prevalence Among
Vaccinated and Unvaccinated Gay, Bisexual, and Other Men Who Have Sex
With Men in Canada’, Sexually transmitted diseases. Wolters Kluwer Health,
(2), p. 123.
Chandler, E. et al. (2018) ‘Epidemiology of any and vaccine-type anogenital
human papillomavirus among 13-26-year-old young men after HPV vaccine in-
troduction’, Journal of Adolescent Health. Elsevier, 63(1), pp. 43-49.
Edelstein, M. et al. (2019) ‘Implementation and evaluation of the human
papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM),
England, April 2016 to March 2017’, Eurosurveillance. European Centre for Dis-
ease Prevention and Control, 24(8), p. 1800055.
Zou, H. et al. (2016) ‘Antibody responses following incident anal and penile
infection with human papillomavirus in teenage men who have sex with men’,
International Journal of Cancer. Wiley Online Library, 139(3), pp. 639-646.
Nyitray, A. G. et al. (2011) ‘The prevalence of genital HPV and factors asso-
ciated with oncogenic HPV among men having sex with men and men having
sex with women and men: the HIM study’, Sexually transmitted diseases. NIH
Public Access, 38(10), p. 932.
Giuliano, A. R. et al. (2015) ‘EUROGIN 2014 roadmap: Differences in
human papillomavirus infection natural history, transmission and
human papillomavirus-related cancer incidence by gender and anatom-
ic site of infection’, International Journal of Cancer. John Wiley & Sons,
Ltd, 136(12), pp. 2752-2760. doi: https://doi.org/10.1002/ijc.29082.
Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, Stern
ME, Lee SK, O’Reilly SF, Hawes SE, Kiviat NB, Koutsky LA. Genital human
papillomavirus infection in men: incidence and risk factors in a cohort
of university students. J Infect Dis. 2007 Oct 15;196(8):1128-36. doi:
1086/521192. Epub 2007 Sep 13. PMID: 17955430.
Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny
ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo
S, Barr E, Haupt RM, Garner EI, Guris D. External genital human papillo-
mavirus prevalence and associated factors among heterosexual men on
continents. J Infect Dis. 2011 Jan 1;203(1):58-65. doi: 10.1093/infdis/
jiq015. PMID: 21148497; PMCID: PMC3086430.
Parada R, Morales R, Giuliano AR, Cruz A, Castellsagué X, Lazcano-Ponce
E. Prevalence, concordance and determinants of human papillomavirus
infection among heterosexual partners in a rural region in central Mexi-
co. BMC Infect Dis. 2010 Jul 28;10:223. doi: 10.1186/1471-2334-10-223.
Erratum in: BMC Infect Dis. 2011;11:25. PMID: 20667085; PMCID:
PMC2941497.
Wendland, E. M. et al. (2020) ‘Prevalence of HPV infection among
sexually active adolescents and young adults in Brazil: The POP-Brazil
Study’, Scientific reports. Nature Publishing Group, 10(1), pp. 1-10.
Wittawatmongkol, O. et al. (2019) ‘Human papillomavirus infection
among male adolescents and young adults with perinatally-acquired HIV
and without HIV in Thailand’, International journal of STD & AIDS. SAGE
Publications Sage UK: London, England, 30(10), pp. 960-968.
Giuliano, A. R. et al. (2008) ‘Age-specific prevalence, incidence, and
duration of human papillomavirus infections in a cohort of 290 US men’, The
Journal of infectious diseases. The University of Chicago Press, 198(6),
pp. 827-835.
Rodríguez-Álvarez, M. I. et al. (2018) ‘Prevalence and Risk Factors of
Human Papillomavirus in Male Patients: A Systematic Review and Meta-
Analysis’, International Journal of Environmental Research and Public
Health . doi: 10.3390/ijerph15102210.
Drolet, M. et al. (2019) ‘Population-level impact and herd effects follow-
ing the introduction of human papillomavirus vaccination programmes:
updated systematic review and meta-analysis’, The Lancet, 394(10197),
pp. 497-509. doi: https://doi.org/10.1016/S0140-6736(19)30298-3.
Mehanna, H. et al. (2019) ‘Human Papillomavirus (HPV) Vaccine Ef-
fectiveness and Potential Herd Immunity for Reducing Oncogenic
Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-
sectional Study’, Clinical Infectious Diseases, 69(8), pp. 1296-1302. doi:
1093/cid/ciy1081.
Wolff, E. et al. (2018) ‘Cost-effectiveness of sex-neutral HPV-vacci-
nation in Sweden, accounting for herd-immunity and sexual behaviour’,
Vaccine, 36(34), pp. 5160-5165. doi: https://doi.org/10.1016/j.vaccine.
07.018.
Daling, J. R. et al. (2004) ‘Human papillomavirus, smoking, and sexu-
al practices in the etiology of anal cancer’, Cancer. Wiley Online Library,
(2), pp. 270-280.
Arbyn, M., Xu, L., et al. (2018) ‘Prophylactic vaccination against
human papillomaviruses to prevent cervical cancer and its precursors’,
Cochrane database of systematic reviews. John Wiley & Sons, Ltd,
